Tvardi Therapeutics to Participate in the TD Cowen 45th Annual Health Care Conference


HOUSTON, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Tvardi Therapeutics, Inc. (“Tvardi”), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat fibrosis-driven diseases, today announced that it will participate in the TD Cowen 45th Annual Health Care Conference. Tvardi management will host investor one-on-one investor meetings on March 3 – 5, 2025.

More:
Tvardi Therapeutics to Participate in the TD Cowen 45th Annual Health Care Conference

Related Posts